In Vitro Inhibition Of Human Immunodeficiency Virus Type 1 By A Combination Of Delavirdine (U-90152) With Protease Inhibitor U-75875 Or Interferon-
- 1 January 1995
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 171 (1) , 61-67
- https://doi.org/10.1093/infdis/171.1.61
Abstract
Delavirdine (bisheteroarylpiperazine, U-90152), a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), was evaluated in a two-drug combination with recombinant human interferon-a (IFN-α) or the peptidomimetic protease inhibitor U-75875 against HIV-l replication in vitro. Viral growth was assayed in a CD4+ T cell line (H9) infected with HIVIIIB and in human peripheral blood mononuclear cells infected with the clinical isolate HIVJRCSF . Drug synergy, estimated by the combination index method and the method of Pritchard and Shipman, was observed when delavirdine was combined with U-75875 or IFN-α over a range of drug concentrations (delavirdine: 0.001, 0.003, 0.01, 0.03 µM ; U-75875: 0.01, 0.03,0.1,0.3, 1.0 µM ; IFN-α: 2,6, 17, and 50 or 10,30, 100, and 300 IU/mL). The combinations showed no detectable drug antagonism or cytotoxicity. These in vitro synergy data support the potential use of delavirdine with either a protease inhibitor or IFN-α in patients with AIDS.Keywords
This publication has 0 references indexed in Scilit: